MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2004.10.113

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2004

Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis.

Ströbel Philipp, Bauer Andrea, Puppe Bernhard, Kraushaar Til, Krein Axel, Toyka Klaus, Gold Ralf, Semik Michael, Kiefer Reinhard, Nix Wilfred, Schalke Berthold, Müller-Hermelink Hans Konrad, Marx Alexander

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Thymic epithelial tumors (TET) are rare epithelial neoplasms of the thymus with considerable histologic heterogeneity. This retrospective study focused on the correlation of WHO-defined TET histotypes with survival and tumor recurrence in a large cohort of patients receiving different modes of treatment.

PATIENTS AND

METHODS

Two hundred twenty-eight patients were followed for up to 21 years (median, 60 months; range, 1 to 252 months) after primary surgery. Forty-two patients received adjuvant radiotherapy (mean dose, 53 Gy), and 33 patients received adjuvant chemotherapy.

RESULTS

Seventy-six (88%) of 86 patients with WHO type A, AB, and B1 thymomas were treated by surgery alone, with three tumor relapses after 3 to 10 years (median, 3.4 years). Twelve of 67 patients with WHO type B2 and B3 thymomas in Masaoka stages I and II were treated by adjuvant radiotherapy without evidence of tumor recurrence after 1 to 12 years (median, 4 years). Among 75 patients with B2 and B3 thymomas with incomplete resection or a tumor stage III or higher, the recurrence rate was 34% (n = 23) after 0.5 to 17 years (median, 5 years) in patients receiving adjuvant radiochemotherapy, compared to 78% (seven of nine patients) in patients without adjuvant radiochemotherapy. Incomplete tumor resection was associated with a high recurrence rate (65%) and a poor prognosis (P <.01).

CONCLUSION

The long-term outcome of TET patients is related to tumor stage, WHO histotype, completeness of surgical removal, and type of treatment. Prospective trials are warranted to formally address the efficacy of adjuvant therapy in the treatment of localized and advanced malignant TETs.

Для цитирования: Ströbel Philipp, Bauer Andrea, Puppe Bernhard, Kraushaar Til, Krein Axel, Toyka Klaus, Gold Ralf, Semik Michael, Kiefer Reinhard, Nix Wilfred, Schalke Berthold, Müller-Hermelink Hans Konrad, Marx Alexander. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. DOI: 10.1200/jco.2004.10.113.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.